Diabetic Retinopathy, the leading cause of blindness in working-age adults.

DR progresses without warning, making early detection through autonomous AI the most effective way to stop irreversible vision loss.

What is Diabetic Retinopathy?

Diabetic retinopathy (DR) is a prevalent eye condition unique to those with diabetes, caused by blood sugar fluctuations that damage retinal blood vessels and neurons. As the leading cause of blindness in the working-age population, it affects one in three people living with diabetes globally. The disease progresses from leaking vessels and microaneurysms to the growth of fragile new vessels, which can lead to retinal detachment and permanent vision loss.

Fundus photo showing retina affected by suspected vision-threatening diabetic retinopathy with visible preretinal hemorrhage and laser photocoagulation.

Why early identification of DR matters

The most troubling aspect of DR is that early stages typically result in no noticeable symptoms, yet a lack of symptoms does not indicate lack of damage. Early identification is vital because by the time vision is noticeably impaired, the prognosis for recovery is much more grim. Periodic screenings are essential to catch the issue early, as DR is highly treatable in its initial stages, allowing patients to preserve their sight and long-term independence.

How AI supports DR awareness and care pathways

AI technology like EyeArt supports care pathways by providing autonomous, non-invasive screenings that identify DR without requiring human interpretation. This scalable model enables universal access at the point of care, bridging the gap for millions who do not see an eye specialist. By delivering accurate results in under 30 seconds, AI ensures that high-risk patients are fast-tracked to specialists, transforming a standard visit into a life-saving event.

95%

of vision loss from DR can be prevented with early detection and timely treatment (source)

1 in 3

people living with diabetes are affected by DR (source)

60%

of people with diabetes do not get annual eye exams (source)

ECONOMIC IMPACT

Prevent blindness

Extend access

Generate preventive care revenue

Reduce downstream cost

Improve quality metrics

BUILD TO EXPAND

Same platform

Same camera(s)

Same workflow

New diseases/cameras with added clearances

Learn more about our full-spectrum solution.

Solutions

Eyenuk has the most validated autonomous AI in healthcare.

See the proof with your own eyes.

FDA 510(k)-cleared: The only autonomous AI for simultaneous mtmDR and vtDR detection

Disease detection accuracy: Over 90% sensitivity and specificity demonstrated in multiple, large independent clinical studies

Global compliance: EU MDR Class IIb for DR, AMD, and GOND detection

Secure and certified: SOC 2 Type 2, HIPAA, GDPR, and ISO 13485:2016 (MDSAP) compliant for maximum data safety

Real-world scale: 500K+ patients screened across primary care, diabetes centers, and specialty clinics worldwide

Camera compatibility: Indicated for use with multiple leading retinal camera manufacturers

View the clinical evidence for yourself.

Clinical Evidence

Transform every eye into a gateway to understanding.

Start autonomous retinal AI screening in your clinic today.